Immune-Related Adverse Events for GI Toxicity - Colitis
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۲۰ • واحد: stools/day
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- —1–1
- —2–2
- —3–3
- —4–4
The Immune-Related Adverse Events for GI Toxicity - Colitis calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include stool increase per day. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Grades severity of colitis secondary to immune checkpoint inhibitor therapy and provides management recommendations
Clinical Indication
The Immune-Related Adverse Events for GI Toxicity - Colitis is indicated for bedside clinical practice to support Grades severity of colitis secondary to immune checkpoint inhibitor therapy and provides management recommendations. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care. Clinical exclusion: Stool studies should exclude infectious causes (C. diff, CMV, parasites).
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Most frequently occurs 5-10 weeks after ICPi treatment initiation.
Grading based on stool frequency increase over baseline, presence of incontinence, functional impact, and hospitalization needs: Grade 1 (<4 stools/day increase), Grade 2 (4-6 stools/day increase), Grade 3 (≥7 stools/day increase, incontinence, limiting self-care), Grade 4 (life-threatening consequences)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| stool_increase_per_day | integer | Yes | Increase in number of stools per day over baseline(stools/day) |
| incontinence_present | string | Yes | Presence of fecal incontinence |
| functional_impact | string | Yes | Impact on activities of daily living and self-care |
| hospitalization_indicated | string | Yes | Clinical indication for hospitalization |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | — | Mild - Increase of <4 stools per day over baseline |
| 2–2 | — | Moderate - Increase of 4-6 stools per day over baseline |
| 3–3 | — | Severe - Increase of ≥7 stools per day, incontinence, limiting self-care |
| 4–4 | — | Life-threatening - Life-threatening consequences, urgent intervention required |
Evidence-Based References (EBM)
- Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.DOI: 10.1200/JCO.2017.77.6385
- Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.DOI: 10.6004/jnccn.2020.0012
- Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.DOI: 10.1001/jamaoncol.2018.3923
- Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015 Aug;42(4):406-17. doi: 10.1111/apt.13281.DOI: 10.1111/apt.13281
Related calculators
- Immune-Related Adverse Events for Lung Toxicity - Pneumonitis
- Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism
- Immune-Related Adverse Events for GI Toxicity - Hepatitis
- Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus
- Immune-Related Adverse Events for Renal Toxicities - Nephritis